Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Not Applicable

Recruiting

• Conditions: ITP - Immune Thrombocytopenia
• Interventions: Drug: Eltrombopag

• Registration Number: NCT07093606
• Lead Sponsor: Sohag University

Brief Summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study Start: 2025-07-14
• Study First Submitted: 2025-07-23
• Study First Submitted QC: 2025-07-23
• Last Update Submitted: 2025-07-23
• Study First Posted: 2025-07-30
• Last Update Posted: 2025-07-30
• Primary Completion: 2026-01-20
• Study Completion: 2026-01-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
this group will receive Eltrombopag tabelts	Eltrombopag	ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .

Primary Outcome Measures

Name	Time	Method
•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.	3-6 months after receiving eltombopag	the incidence and severity of liver dysfunction in ITP patients

Trial Locations

Locations (1)

Sohag university hospital; 🇪🇬 Sohag, Egypt